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Background
Retrospective molecular profiling of untreated Diffuse
Large B-Cell Lymphoma (DLBCL) samples has recog-
nised distinct sub-classifications of this disease, each
with unique biological features and clinical outcomes.
Objectives
(i) To demonstrate superior clinical efficacy, of bortezomib
in combination with rituximab and CHOP (RB-CHOP)
versus R-CHOP for the treatment of previously untreated
patients with DLBCL.
(ii) To assess whether the molecular phenotype deter-
mines benefit from the addition of bortezomib.
Methods
The trial uses an adaptive design and aims to recruit
940 patients across 100 sites in the UK and Switzerland
(currently recruited 398 patients). After being profiled
within real time (during cycle 1), ABC, GCB and unclas-
sifiable molecular phenotype patients are randomised to
receive RB-CHOP or R-CHOP with equal allocation.
Two interim analyses will be carried out to stop the
good prognosis GCB group early if required using a
Case Morgan [1] analysis:
(i) The first will be a safety analysis performed after the
first 55 GCB RB-CHOP patients have been followed for 6
months. If 6 month PFS<80%, the GCB group will close.
(ii) The second will be for futility in the GCB group
and performed after the first 73 GCB RB-CHOP patients
have been followed for 1 year. If 1 year PFS<85%, the
GCB group will close.
If the GCB group closes the trial will then be modified
to a randomised Phase II trial in ABC patients and sam-
ple size calculations will be revised.
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